Pazopanib activity confirmed in EWSR1-NFATC2 bone sarcoma

A new case report was published in Oncoscience (Volume 10) on September 20, 2023, entitled, “Activity of pazopanib in EWSR1-NFATC2 translocation-associated bone sarcoma.”

BCMA-GPRC5D CAR-T Cells by Guangzhou Bio-gene Technology for Refractory Multiple Myeloma: Likelihood of Approval

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes

September 14, 2023

Scholar Rock claims success in Phase 3 spinal muscular atrophy study, stock soars

Sign up for free to read a limited number of articles each month. Pick what newsletters get delivered to your inbox each week. Biopharma ENDPOINTS

October 8, 2024

Timing and cost of new vaccines vary by virus and health insurance status

As summer edges toward fall, thoughts turn to, well, vaccines.

August 24, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.